Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380211 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 660
- Enrollment target
NCT00380211 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 660 participants.
The verdict
NCT00380211, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 660 participants
- Enrollment target
Study Summary
The purpose of this trial is to describe the immunogenicity, the safety, and tolerability of FluLaval™ TR and Fluarix®, the latter serving as active comparator. The results will be compared to a standard immune response criteria, for both young and elderly populations.
Interventions
- BIOLOGICAL Fluarix
- BIOLOGICAL Influenza vaccine (A/H3N2, A/H1N1, and B strains)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2006-09 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00380211
The ClinicalTrials.gov registry entry for NCT00380211 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluarix is the first listed.
NCT00380211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00380211 about?
NCT00380211 is a clinical study titled "Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults". The purpose of this trial is to describe the immunogenicity, the safety, and tolerability of FluLaval™ TR and Fluarix®, the latter serving as active comparator. The results will be compared to a standard immune response criteria, for both young and elderly populations.
What is the current status of trial NCT00380211?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 660 participants. The study started on 2006-09. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00380211?
The interventions under investigation include: Fluarix (BIOLOGICAL), Influenza vaccine (A/H3N2, A/H1N1, and B strains) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00380211?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.